A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Status:
RECRUITING
Trial end date:
2031-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.